



UNIVERSITY OF KANSAS MEDICAL CENTER

RAINBOW BOULEVARD AT 39TH STREET
KANSAS CITY, KANSAS 66103 • AREA CODE 913 • ADAMS 6-5252

CLINICAL PHARMACOLOGY STUDY UNIT

April 10, 1969

RECEIVED

Herbert C. Ley, M.D.
Commissioner
Food and Drug Administration
Washington, D. C. 20204

APR 18 1969
DRUG EFFICACY STUDY
IMPLEMENTATION
TASK FORCE M-16

Dear Dr. Ley:

I have been reading, with increasing alarm, the numerous tirades and testimonials of practicing physicians concerning the attempt by the FDA to implement the NAS-NRC report on combination antibiotic products. I am also a practicing physician and treat patients on a daily basis as well as investigate the clinical effects and responses of drugs. To my knowledge, the increased effectiveness of two antibiotics of over only one, has been demonstrated that with organisms resistant to many antibiotics, the judicious administration of two or more carefully selected antibiotics can be life saving. However, this type of approach must be carefully tailored to the *in vitro* sensitivity studies for that particular organism and cannot be accomplished with the available multiple antibiotic preparations.

Please accept this letter as my vigorous support for your stand in this matter.

Sincerely yours,

Daniel L. Azarnoff
Daniel L. Azarnoff, M.D.
Professor of Medicine and
Pharmacology

DLA/bt